https://www.selleckchem.com/products/a2ti-2.html
Introduction Plasma androgen receptor (AR) copy number (CN) status identifies castration-resistant prostate cancer (CRPC) patients with worse outcome on abiraterone/enzalutamide. However, the impact of AR CN changes on clinical outcome in CRPC is unknown. Materials and Methods Plasma samples from 73 patients treated with abiraterone or enzalutamide were collected at baseline and at the time of progression disease (PD). Droplet digital polymerase chain reaction was used to assess AR CN status. Results We showed that 11 patients (15.1%) ch
Gefällt mir
Kommentar
Teilen
